Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06685835 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Insmed Incorporated.
- Active
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
- 20
- Study locations
NCT06685835 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Insmed Incorporated. The registered enrollment target is 214 participants, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06685835, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Insmed Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brensocatib
Study Locations (20)
Florida
- USA026 - Coral Gables
- USA027 - Hollywood
- USA021 - Margate
- USA018 - Miami
- USA025 - Ocala
- USA004 - Tampa
- USA010 - Weston
Georgia
- USA028 - Atlanta
- USA011 - Sandy Springs
Michigan
- USA012 - Detroit
- USA024 - Fort Gratiot
Arizona
- USA001 - Phoenix
California
- USA007 - Sacramento
Indiana
- USA003 - Plainfield
Louisiana
- USA002 - Baton Rouge
Massachusetts
- USA017 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2026-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06685835
The ClinicalTrials.gov registry entry for NCT06685835 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (64% lower). The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06685835 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT06685835 about?
NCT06685835 is a clinical study titled "A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)". The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
What is the current status of trial NCT06685835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2024-12-16. Estimated completion is 2026-11-17.
What conditions does trial NCT06685835 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06685835?
The interventions under investigation include: Placebo (DRUG), Brensocatib (DRUG).
Who is sponsoring clinical trial NCT06685835?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06685835 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.